Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Aurinia Pharmaceuticals Inc (AUP) NPV

Sell:26.30 CAD Buy:27.00 CAD Change: 0.15 CAD (0.55%)
Market closed |  Prices as at close on 21 February 2020 | Switch to live prices |
Sell:26.30 CAD
Buy:27.00 CAD
Change: 0.15 CAD (0.55%)
Market closed |  Prices as at close on 21 February 2020 | Switch to live prices |
Sell:26.30 CAD
Buy:27.00 CAD
Change: 0.15 CAD (0.55%)
Market closed |  Prices as at close on 21 February 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Contact details

Address:
1203-4464 Markham St
VICTORIA
V8Z 7X8
Canada
Telephone:
+1 (250) 7084272
Website:
https://www.auriniapharma.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AUP
ISIN:
CA05156V1022
Market cap:
2.83 billion CAD
Shares in issue:
107.07 million
Sector:
Biotechnology
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • George Milne
    Executive Chairman of the Board
  • Peter Greenleaf
    Chief Executive Officer, Director
  • Dennis Bourgeault
    Chief Financial Officer
  • Michael Martin
    Chief Operating Officer
  • Robert Huizinga
    Executive Vice President - Corporate Development
  • Erik Eglite
    Senior Vice President, Chief Compliance Officer, General Counsel
  • Neil Solomons
    Chief Marketing Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.